WHO ARE WE?
We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based at our 3 sites – in Europe and US – are devoted to supporting innovative projects and help reduce overall timelines and costs.
Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.
We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.
Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.
We place the client at the heart of everything we do. We implement strategies to achieve best-in-class customer experience. A team of experts is dedicated to your project to provide you with the best innovative solutions adapted to your needs.
first viral vector facility in Europe
(France & USA)
years of experience
in viral vectors
- Fill & Finish up to
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897.
As a pioneer, we have been developing and producing viral vectors since the 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the ultimate goal of fighting smallpox and several types of cancer.
We have continuously added new viruses to our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.
More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world.
Bionetics Research Laboratory was established
Acquired by Litton Industries.
Expanded activities in retrovirus and cancer research
Organon Teknika acquires R&D and diagnostic assets, renames company ABL
ABL acquired by bioMérieux.
ABL becomes an Institut Mérieux Company
ABL spun out from bioMérieux as a sister company, under Institut Mérieux
ABL opens Rockville, MD headquarters
ABL acquires Platine Pharma in Lyon and built GCLP testing labs
Creation of the first ABL entity in France through the acquisition of the Transgene production asset in Strasbourg*
* Expansion of ABL capabilities through the viral vector manufacturing plant, certified GMP in 1995.
Creation of the second ABL entity in France through the acquisition of the Accinov innovative platform in Lyon
ABL is fully owned by Institut Mérieux.
OUR MISSION & VISION
OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.
OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.
WHAT DO WE OFFER?
Your solution provider
Developing and manufacturing viral vectors for over 25 years
Dedicated project management
Effective quality control capabilities essential for your success
Flexibility within our contracts
Talented teams to deliver the highest level of services
OUR LEADERSHIP TEAM
General Director ABL Europe / Chief Operating Officer
Chief Finance Officer
Chief Technology Officer
Chief Business Officer
Legal / Compliance Director
Human Ressources Director